In a small, open-label trial in people with mild to moderate, dominantly inherited Alzheimer’s disease (DIAD), the tau immunotherapy etalanetug almost abolished markers of neurofibrillary tangles in ...
Decades before a person's first memory problems surface, changes happen in their biofluids that suggest their path toward dementia has already been forged. Two studies identified proteomic signals, in ...
A commercially available plasma phosphorylated-tau217 assay was highly accurate in identifying Alzheimer disease pathology. The plasma phosphorylated tau (p-tau) at threonine 217 (p-tau217) ...
CSF-ctDNA was detected in 59% of cases and showed high concordance (84%) with tumor mutations. Lower variant allelic frequency in CSF-ctDNA was associated with significantly worse survival outcomes.
The Brighterside of News on MSN
FDA-approved drug may slow brain cell death in Alzheimer’s patients
Long before memory problems appear, your brain may already be losing neurons. That is the unsettling message from new work by ...
CNSide® may catalyze LM treatment initiation, allow physicians to adapt treatment with real time shifts in tumor biology, and enable personalized cancer therapy HOUSTON, Aug. 14, 2025 (GLOBE NEWSWIRE) ...
Exploring the genetic blueprint of cerebrospinal fluid proteins, this study uncovers new markers and therapeutic targets that may unlock advancements in Alzheimer’s diagnosis and care. Study: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback